| 06/23 | GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel.. | PU |
| 06/23 | GALAPAGOS : increases share capital through subscription right exercises - Form 6-K | PU |
| 06/22 | TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call | CI |
| 06/22 | Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2.. | MT |
| 06/21 | Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions | MT |
| 06/21 | Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce.. | GL |
| 06/21 | Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce.. | GL |
| 06/21 | Galapagos NV acquired CellPoint B.V. from ND Capital and others for approximately €.. | CI |
| 06/21 | Galapagos NV acquired Abound Bio, Inc. for $14 million. | CI |
| 06/20 | Galapagos increases share capital through subscription right exercises | GL |
| 06/20 | Galapagos increases share capital through subscription right exercises | AQ |
| 06/20 | Galapagos NV announced that it expects to receive €1.459507 million in funding | CI |
| 06/02 | GALAPAGOS : receives transparency notification from FMR LLC - Form 6-K | PU |
| 06/01 | Galapagos receives transparency notification from FMR LLC | GL |
| 06/01 | Galapagos receives transparency notification from FMR LLC | AQ |
| 05/31 | GALAPAGOS : to showcase commitment to rheumatoid arthritis care at the upcoming European L.. | PU |
| 05/25 | Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European .. | GL |
| 05/24 | Galapagos In-Licenses Drug Targets for Inflammatory Bowel Disease From Scipher | MT |
| 05/20 | Intervest Offices & Warehouses Extends Lease Deals For Office Portfolio In Belgium | MT |
| 05/09 | RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating | MT |
| 05/06 | Galapagos creates new subscription right plans | GL |
| 05/06 | Galapagos creates new subscription right plans | AQ |
| 05/06 | TRANSCRIPT : Galapagos NV, Q1 2022 Earnings Call, May 06, 2022 | CI |
| 05/05 | Galapagos demonstrates regulatory and commercial progress in Q1 2022 | GL |
| 05/05 | Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 04/27 | GALAPAGOS : announces appointment of Dr. Paul Stoffels as Chairman of the board - Form 6-K | PU |
| 04/26 | Galapagos Names CEO As Chairman Under New Governance Structure | MT |
| 04/26 | Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board | GL |
| 04/26 | Galapagos NV Announces Executive Appointments | CI |
| 04/12 | E-therapeutics Achieves Key Milestones Under Collaboration with Galapagos | MT |
| 04/12 | E-therapeutics plc Announces A Key Milestone in Its Collaboration with Galapagos | CI |
| 04/11 | SUBJECT : Galapagos AGM/EGM 2022 April 11th, 2022 - Form 6-K | PU |
| 04/11 | GALAPAGOS : Chairman letter to shareholders | PU |
| 04/01 | GALAPAGOS : Glpg egm & agm 2022 | PU |
| 03/28 | Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION .. | CI |
| 03/28 | Galapagos' Jyseleca Gets Japanese Nod For Ulcerative Colitis Treatment | MT |
| 03/28 | Jyseleca® approved in Japan for ulcerative colitis | AQ |
| 03/25 | GALAPAGOS : — Proposal of one-tier board structure & appointment of three new directo.. | PU |
| 03/24 | GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31.. | PU |
| 03/24 | CORRECTION : Galapagos publishes 2021 annual report and announces extraordinary and annual.. | GL |
| 03/24 | Galapagos publishes 2021 annual report and announces extraordinary and annual sharehold.. | AQ |
| 03/24 | GALAPAGOS : increases share capital through subscription right exercises - Form 6-K | PU |
| 03/20 | GALAPAGOS NV(ENXTAM : GLPG) dropped from FTSE All-World Index | CI |
| 03/18 | Galapagos increases share capital through subscription right exercises | AQ |
| 02/28 | RBC Cuts Price Target on Galapagos to $60 From $63, Maintains Sector Perform Rating | MT |
| 02/25 | TRANSCRIPT : Galapagos NV, 2021 Earnings Call, Feb 25, 2022 | CI |
| 02/24 | GALAPAGOS : 2021 results set stage for future growth - Form 6-K | PU |
| 02/24 | Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 02/24 | Galapagos 2021 results set stage for future growth | GL |
| 02/07 | GALAPAGOS : receives transparency notification from EcoR1 Capital - Form 6-K | PU |
| 02/07 | GALAPAGOS : provides further insights into the treatment of ulcerative colitis at the Euro.. | PU |
| 02/03 | Galapagos receives transparency notification from EcoR1 Capital | AQ |
| 02/02 | Galapagos provides further insights into the treatment of ulcerative colitis at the Eur.. | AQ |
| 02/02 | Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the Eur.. | CI |
| 01/28 | Bryan Garnier Double Upgrades Galapagos NV to Buy From Sell, Lowers PT to 65 Euros From.. | MT |
| 01/27 | Health Care Outperform Amid Fading Thursday Markets | MT |
| 01/27 | Top Midday Gainers | MT |
| 01/27 | Health Care Stocks Still Outperforming Amid Fading Thursday Markets | MT |
| 01/27 | SECTOR UPDATE : Health Care | MT |
| 01/27 | Galapagos Names Former Johnson & Johnson Executive Paul Stoffels CEO; Shares Soar | MT |
| 01/27 | GALAPAGOS : appoints Paul Stoffels as Chief Executive Officer - Form 6-K | PU |
| 01/26 | Galapagos Appoints Former Johnson & Johnson Exec to Succeed Retiring CEO | MT |
| 01/26 | Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO | RE |
| 01/26 | GALAPAGOS : creates new subscription right plan - Form 6-K | PU |
| 01/26 | Galapagos creates new subscription right plan | AQ |
| 01/26 | Galapagos appoints Paul Stoffels as Chief Executive Officer | AQ |
| 01/26 | Galapagos NV Appoints Paul Stoffels as Chief Executive Officer | CI |
| 01/19 | GALAPAGOS : JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WIT.. | PU |
| 01/18 | Galapagos Wins Expanded UK Nod for Inflammatory Bowel Disease Drug Jyseleca | MT |
| 01/18 | Galapagos Gets UK Approval for Jyseleca to Treat Ulcerative Colitis | MT |
| 01/18 | Jyseleca®▼ (filgotinib) licensed for the treatment of adult patients with moderat.. | AQ |
| 01/18 | Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Ag.. | CI |
| 01/14 | Galapagos Supervisory Board Creates 30,000 Subscription Rights Plan | MT |
| 01/13 | GALAPAGOS : creates new subscription right plan - Form 6-K | PU |
| 01/13 | Galapagos creates new subscription right plan | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
